Previous 10 | Next 10 |
2023-06-16 20:41:21 ET Summary Xeris Biopharma Holdings Inc is a growing healthcare company with strong revenue growth and a solid balance sheet, making it an attractive investment option. XERS has a range of successful products, such as Glucagon and Gvoke, and is aggressively sec...
2023-06-15 17:38:38 ET Gainers: Adobe ( ADBE ) +5% . Arcturus Therapeutics ( ARCT ) +5% . Xeris Biopharma Holdings ( XERS ) +4% . Castle Biosciences ( CSTL ) +4% . Enovix Corporation ( ENVX ) +4% . Losers: Mil...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a f...
2023-05-09 14:24:02 ET Xeris Biopharma Holdings, Inc. (XERS) Q1 2023 Earnings Conference Call May 09, 2023, 08:30 AM ET Company Participants Allison Wey - Senior Vice President, Investor Relations, and Corporate Communications Paul Edick - Chairman and Chief Executiv...
2023-05-09 07:03:17 ET Xeris Pharmaceuticals press release ( NASDAQ: XERS ): Q1 GAAP EPS of -$0.12 beats by $0.05 . Revenue of $33.2M (+51.5% Y/Y) beats by $2.43M . FY2023 Outlook : Total revenue of $135M-$165M vs. consensus of $146.9M; cash utilization fro...
Achieved first quarter total revenue of $33.2M representing 50% growth compared to Q1 2022 Ended Q1 2023 with $95.1M in cash, cash equivalents, and short-term investments Affirms 2023 guidance: total revenue of $135M-$165M; cash utilization from operating activities of $57M-$77M; ...
2023-05-08 12:35:57 ET Xeris Pharmaceuticals ( NASDAQ: XERS ) is scheduled to announce Q1 earnings results on Tuesday, May 9th, before market open. The consensus EPS Estimate is -$0.15 (+40.0% Y/Y) and the consensus Revenue Estimate is $30.77M (+40.4% Y/Y). Over the la...
Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the C...
2023-04-18 07:42:03 ET Xeris Biopharma ( NASDAQ: XERS ) said that the U.S. Patent and Trademark Office issued a patent covering its XeriSol formulations. The Patent Number 11,590,205 is titled 'Methods for producing stable therapeutic glucagon formulations in aprotic pola...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the U.S. Patent and Trademark Office has issued US Paten...
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track reco...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2024, the Compensation Committee of Xeris’ Boar...
In patients with Cushing’s syndrome maintained on Recorlev, a lower baseline mUFC was associated with higher cortisol normalization rate. Lower mUFC at baseline was also associated with lower maintenance dose requirements and lower rates of potentially clinically important liver-re...